Pulsenmore Signs New Agreement with TLC Perinatal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Pulsenmore announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women's ultrasound practice in Maryland, as part of its growing U.S. rollout. In early February Pulsenmore, through its U.S. subsidiary, entered into a services agreement with TLC Perinatal PA, which operates in Silver Spring and Germantown, Maryland. Under the agreement, TLC Perinatal will incorporate Pulsenmore's Early Screening home ultrasound services into its care model, allowing patients to perform ultrasound scans at home as part of a physician-directed hybrid care pathway that incorporates telehealth and scheduled in-clinic visits. TLC Perinatal is a specialized maternal-fetal medicine practice focused on diagnostic imaging and consultative care for pregnancies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSM
Wall Street analysts forecast PLSM stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 6.590
Low
Averages
High
Current: 6.590
Low
Averages
High
No data
About PLSM
Pulsenmore Ltd is an Israel-based medical equipment company. The Company engaged in the field of research and development activity, production, marketing and sales worldwide of solutions and technologies that concern portable ultrasound devices for home use by the patient for a remote physical examination or monitoring using telehealth technology. he company has developed and sells two miniaturized ultrasound systems: the first is called PulseNmore ES, for performing home ultrasound tests for pregnant women; and the second is called PulseNmore FC, for performing a self-test of the size of the follicles in women who are in the process in vitro fertilization. Both systems make use of a smart mobile phone and make the test accessible without the need o visit in clinic or hospital, while being able to transfer film for the doctor, the treating medical team or the hotline online. Moreover the COmpany delivers software for its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulsenmore Enters Private Placement Agreement with Institutional Investor
- Private Placement Agreement: Pulsenmore has entered into a private placement agreement with a healthcare-focused institutional investor to sell 1.56 million ordinary shares and warrants, expected to generate approximately $7.5 million in gross proceeds, showcasing the company's capital market capabilities.
- Premium Pricing: The purchase price of $4.80 per share meets Nasdaq's minimum price requirement, indicating investor confidence in Pulsenmore's future despite a 12% premarket decline in share price, reflecting market volatility.
- Clear Use of Proceeds: The funds raised will be allocated for marketing, commercialization efforts, working capital, and general corporate purposes, demonstrating the company's strategic planning and resource allocation for future growth.
- Transaction Timeline: The transaction is expected to close on or about June 26, 2026, indicating that Pulsenmore will have new capital injections to support its business expansion plans in the coming years.
See More
Pulsenmore Secures $7.5 Million in Private Placement Financing
- Financing Size: Pulsenmore has entered into a securities purchase agreement with an institutional investor for the sale of 1,562,500 ordinary shares and accompanying warrants, with expected gross proceeds of $7.5 million, reflecting strong market confidence in its home ultrasound technology.
- Market Expansion Plans: CEO Elazar Sonnenschein stated that this financing will support the company's expansion in the U.S. market, aiming to increase market penetration and drive long-term growth, indicating a positive outlook for future development.
- Warrant Details: The warrants associated with this financing have an exercise price of $4.80 per share, are immediately exercisable, and will expire in five years, enhancing potential returns for investors while providing the company with additional capital flexibility.
- Use of Proceeds: Pulsenmore intends to use the net proceeds for marketing, commercialization activities, and general corporate purposes, demonstrating the company's strategic intent to enhance operational efficiency and market competitiveness.
See More
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
Pulsenmore Partners with Ouma Health to Expand U.S. Maternal Health Market
- Market Expansion Opportunity: Pulsenmore's collaboration with Ouma Health will significantly enhance its presence in the U.S. maternal health market, particularly benefiting expectant mothers in remote areas lacking maternal care services, thereby creating new growth opportunities.
- Technological Integration Advantage: Ouma Health will utilize Pulsenmore's FDA-certified home ultrasound platform, enabling necessary prenatal monitoring for mothers in remote regions, thus improving the accessibility and quality of healthcare services.
- Stock Surge Reaction: Following the announcement of the partnership, Pulsenmore's stock (PLSM) skyrocketed over 200% on Wednesday, reflecting strong market optimism towards the collaboration, despite the company's stock having lost more than half its value since going public.
- Importance of Virtual Care Models: With 35% of U.S. counties classified as maternal care deserts, the integration of virtual care models with home ultrasound technology will play a crucial role in bridging care gaps for expectant mothers, further advancing Pulsenmore's strategic objectives.
See More
Ouma Health Partners with Pulsenmore to Enhance Home Ultrasound in Maternity Care
- Strategic Partnership: Pulsenmore has formed a strategic partnership with Ouma Health to integrate FDA-authorized home ultrasound technology into Ouma's virtual maternity care model, aiming to enhance the adoption of home ultrasound in prenatal care across the U.S.
- Technological Innovation: By incorporating home ultrasound technology, Ouma Health will be able to offer more convenient prenatal monitoring services, thereby improving the care experience for expectant mothers while reducing healthcare costs.
- Market Expansion: This collaboration provides Pulsenmore with a scalable pathway to promote home ultrasound technology in the U.S. market, which is expected to significantly increase its market penetration and brand influence.
- Industry Impact: The widespread adoption of home ultrasound technology is anticipated to transform traditional prenatal care models, enhancing overall accessibility and efficiency of healthcare services, aligning with the current trend of digital transformation in the healthcare industry.
See More
Pulsenmore Partners with Ouma Health to Advance Home Ultrasound Technology
- Strategic Partnership: Pulsenmore has formed a strategic partnership with Ouma Health to integrate its FDA-authorized home ultrasound technology into Ouma's virtual maternity care platform, aiming to expand access to prenatal care in the U.S., particularly in the 35% of counties classified as maternal care deserts.
- Technology Integration: By bringing prenatal ultrasound monitoring into patients' homes, Ouma Health enhances the prenatal monitoring experience while maintaining continuous connection with clinical teams, thereby improving patient engagement and care coordination.
- Market Potential: This collaboration not only provides Pulsenmore with a significant opportunity to expand its presence in the U.S. maternal health market but also lays the groundwork for future partnerships with healthcare systems, maternity care providers, and payers seeking innovative maternal health delivery models.
- Patient-Centric Care: As maternal healthcare shifts towards more connected and patient-centered models, the application of home ultrasound technology is poised to become a crucial component of future prenatal care, helping providers enhance patient engagement and broaden service reach.
See More
Pulsenmore Enters Private Placement Agreement with Institutional Investor
- Private Placement Agreement: Pulsenmore has entered into a private placement agreement with a healthcare-focused institutional investor to sell 1.56 million ordinary shares and warrants, expected to generate approximately $7.5 million in gross proceeds, showcasing the company's capital market capabilities.
- Premium Pricing: The purchase price of $4.80 per share meets Nasdaq's minimum price requirement, indicating investor confidence in Pulsenmore's future despite a 12% premarket decline in share price, reflecting market volatility.
- Clear Use of Proceeds: The funds raised will be allocated for marketing, commercialization efforts, working capital, and general corporate purposes, demonstrating the company's strategic planning and resource allocation for future growth.
- Transaction Timeline: The transaction is expected to close on or about June 26, 2026, indicating that Pulsenmore will have new capital injections to support its business expansion plans in the coming years.
See More
Pulsenmore Secures $7.5 Million in Private Placement Financing
- Financing Size: Pulsenmore has entered into a securities purchase agreement with an institutional investor for the sale of 1,562,500 ordinary shares and accompanying warrants, with expected gross proceeds of $7.5 million, reflecting strong market confidence in its home ultrasound technology.
- Market Expansion Plans: CEO Elazar Sonnenschein stated that this financing will support the company's expansion in the U.S. market, aiming to increase market penetration and drive long-term growth, indicating a positive outlook for future development.
- Warrant Details: The warrants associated with this financing have an exercise price of $4.80 per share, are immediately exercisable, and will expire in five years, enhancing potential returns for investors while providing the company with additional capital flexibility.
- Use of Proceeds: Pulsenmore intends to use the net proceeds for marketing, commercialization activities, and general corporate purposes, demonstrating the company's strategic intent to enhance operational efficiency and market competitiveness.
See More
Pulsenmore Soars 280% on Ouma Health Collaboration
- Strategic Partnership: Pulsenmore Ltd. has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the U.S., enabling the integration of its FDA-authorized home ultrasound platform, which is expected to significantly enhance customer satisfaction and strengthen market competitiveness.
- Stock Surge: Following the announcement of the partnership, Pulsenmore's stock soared by as much as 280%, closing up 93.26%, reflecting strong market confidence in its future growth potential.
- Technological Innovation: By introducing ultrasound monitoring into homes, Pulsenmore not only increases the frequency of contact between expectant mothers and their care teams but also potentially drives the adoption of virtual healthcare services, aligning with the industry's shift towards digital transformation.
- Market Outlook: This collaboration marks a significant positioning for Pulsenmore in the rapidly growing virtual healthcare market, likely attracting more investor attention and enhancing its standing within the industry.
See More
Pulsenmore Partners with Ouma Health to Expand U.S. Maternal Health Market
- Market Expansion Opportunity: Pulsenmore's collaboration with Ouma Health will significantly enhance its presence in the U.S. maternal health market, particularly benefiting expectant mothers in remote areas lacking maternal care services, thereby creating new growth opportunities.
- Technological Integration Advantage: Ouma Health will utilize Pulsenmore's FDA-certified home ultrasound platform, enabling necessary prenatal monitoring for mothers in remote regions, thus improving the accessibility and quality of healthcare services.
- Stock Surge Reaction: Following the announcement of the partnership, Pulsenmore's stock (PLSM) skyrocketed over 200% on Wednesday, reflecting strong market optimism towards the collaboration, despite the company's stock having lost more than half its value since going public.
- Importance of Virtual Care Models: With 35% of U.S. counties classified as maternal care deserts, the integration of virtual care models with home ultrasound technology will play a crucial role in bridging care gaps for expectant mothers, further advancing Pulsenmore's strategic objectives.
See More
Ouma Health Partners with Pulsenmore to Enhance Home Ultrasound in Maternity Care
- Strategic Partnership: Pulsenmore has formed a strategic partnership with Ouma Health to integrate FDA-authorized home ultrasound technology into Ouma's virtual maternity care model, aiming to enhance the adoption of home ultrasound in prenatal care across the U.S.
- Technological Innovation: By incorporating home ultrasound technology, Ouma Health will be able to offer more convenient prenatal monitoring services, thereby improving the care experience for expectant mothers while reducing healthcare costs.
- Market Expansion: This collaboration provides Pulsenmore with a scalable pathway to promote home ultrasound technology in the U.S. market, which is expected to significantly increase its market penetration and brand influence.
- Industry Impact: The widespread adoption of home ultrasound technology is anticipated to transform traditional prenatal care models, enhancing overall accessibility and efficiency of healthcare services, aligning with the current trend of digital transformation in the healthcare industry.
See More
Pulsenmore Partners with Ouma Health to Advance Home Ultrasound Technology
- Strategic Partnership: Pulsenmore has formed a strategic partnership with Ouma Health to integrate its FDA-authorized home ultrasound technology into Ouma's virtual maternity care platform, aiming to expand access to prenatal care in the U.S., particularly in the 35% of counties classified as maternal care deserts.
- Technology Integration: By bringing prenatal ultrasound monitoring into patients' homes, Ouma Health enhances the prenatal monitoring experience while maintaining continuous connection with clinical teams, thereby improving patient engagement and care coordination.
- Market Potential: This collaboration not only provides Pulsenmore with a significant opportunity to expand its presence in the U.S. maternal health market but also lays the groundwork for future partnerships with healthcare systems, maternity care providers, and payers seeking innovative maternal health delivery models.
- Patient-Centric Care: As maternal healthcare shifts towards more connected and patient-centered models, the application of home ultrasound technology is poised to become a crucial component of future prenatal care, helping providers enhance patient engagement and broaden service reach.
See More
